Vistagen Therapeutics, Inc. (VTGN)
- Previous Close
4.6700 - Open
4.7200 - Bid 4.6600 x 200
- Ask 4.7000 x 100
- Day's Range
4.6000 - 4.8200 - 52 Week Range
1.6200 - 24.7100 - Volume
193,365 - Avg. Volume
268,941 - Market Cap (intraday)
127.018M - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9600 - Earnings Date Jun 26, 2024 - Jul 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
www.vistagen.comRecent News: VTGN
Performance Overview: VTGN
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTGN
Valuation Measures
Market Cap
126.75M
Enterprise Value
2.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
60.81
Price/Book (mrq)
1.03
Enterprise Value/Revenue
2.34
Enterprise Value/EBITDA
-0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.36%
Return on Equity (ttm)
-44.55%
Revenue (ttm)
1.04M
Net Income Avi to Common (ttm)
-32.07M
Diluted EPS (ttm)
-2.9600
Balance Sheet and Cash Flow
Total Cash (mrq)
126.56M
Total Debt/Equity (mrq)
1.83%
Levered Free Cash Flow (ttm)
-18.72M